title: Induction therapy with antithymocyte serum (NATS) increases graft survival and function in kidneys with initial poor function.
authors.affiliation: Department of Surgery, University of Tennessee Medical Center-Knoxville.
authors.forename: M H
authors.initials: MH
authors.lastname: Goldman
authors.forename: R F
authors.initials: RF
authors.lastname: Regester
authors.forename: M B
authors.initials: MB
authors.lastname: Freeman
authors.forename: B
authors.initials: B
authors.lastname: Tyler
authors.forename: J D
authors.initials: JD
authors.lastname: Tyler
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006084:Graft Rejection; D006085:Graft Survival; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000502:physiology*; D012189:Retrospective Studies
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents